The National Science Foundation (NSF) is an independent federal agency established in 1950 and based in Alexandria, Virginia. It is dedicated to supporting research and education in science and engineering across a wide range of disciplines. The NSF provides significant non-dilutive funding, up to $1.5 million, to startups and small businesses through its America's Seed Fund initiative, which is part of the Small Business Innovation Research (SBIR) program mandated by Congress. With an operating budget of approximately $7.8 billion, the NSF is committed to advancing fundamental research and education, thus fostering innovation and technological development in the United States.

SOSV is a global venture capital firm based in Princeton, New Jersey, founded in 1995. It specializes in early-stage investments, focusing on deep technology innovations that address human and planetary health. The firm operates startup development programs, notably HAX and IndieBio, which provide resources, facilities, and lab equipment to accelerate the growth of promising startups. SOSV supports companies from their inception through various funding stages, including seed and series A rounds, while offering ongoing assistance to help them scale and attract additional investors. By concentrating on revolutionary technologies and cross-border markets, particularly in Asia, SOSV aims to foster significant advancements that benefit humanity and the environment.

MedTech Innovator is the industry’s nonprofit global competition and accelerator for medical device, digital health and diagnostic companies. Our mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator annually features 100 companies that address one or more of the transformative themes identified in an annual survey of leading manufacturers and providers.

The European Innovation Council (EIC), established in 2020 and headquartered in Brussels, Belgium, is dedicated to supporting high-potential innovators, entrepreneurs, small enterprises, and researchers. Its primary focus is on fostering early-stage startups that demonstrate significant environmental, social, and governance (ESG) impacts. The EIC collaborates with private investors to co-invest in ventures, particularly within the deep technology sector, aiming to drive innovation and sustainable development across Europe. By providing financial backing and resources, the EIC seeks to enhance the growth potential of promising startups and contribute to a more innovative and competitive European economy.

The National Institutes of Health (NIH) is a leading biomedical research facility in the United States, operating under the Department of Health and Human Services. Established in 1887 and based in Bethesda, Maryland, NIH is the primary agency responsible for biomedical and health-related research in the country. It comprises 27 separate institutes and centers, each focusing on different disciplines within biomedical science. NIH conducts its own scientific research through the Intramural Research Program and provides significant funding for research at external institutions via the Extramural Research Program. With a workforce that includes 1,200 principal investigators and over 4,000 postdoctoral fellows, NIH has been instrumental in major medical breakthroughs, such as the development of vaccines for hepatitis and human papillomavirus, as well as the discovery of treatments for various health conditions. As the world's largest source of medical research funding, NIH continues to advance scientific knowledge and contribute to public health improvements.

MassChallenge is a global nonprofit startup accelerator headquartered in Boston, Massachusetts, founded in 2009. It supports early-stage entrepreneurs from various industries, including technology, healthcare, and finance, by providing mentorship, resources, and networking opportunities. With locations in countries such as Israel, Mexico, Switzerland, and Texas, MassChallenge operates a non-equity model, allowing startups to retain full ownership while benefiting from expert guidance and connections. The accelerator conducts various programs tailored to specific sectors, such as MassChallenge HealthTech and MassChallenge FinTech, which facilitate partnerships between startups and established enterprises to drive innovation and market growth. Through its extensive global network, MassChallenge aims to strengthen the innovation ecosystem and empower high-potential startups to create meaningful impact.

Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.

EASME is a European Union executive agency that supports small and medium-sized enterprises and promotes innovation in Europe. It manages projects in the areas of small and medium-sized enterprises, as well as the environment, energy, and maritime sectors, funded by COSME, LIFE, and EMFF. EASME organizes the European Sustainable Energy Week and serves industries such as environmental management, energy production, and maritime activities.

Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.

HAX is a venture capital program focused on accelerating hardware startups, operating from San Francisco and Shenzhen. Established in 2012, HAX provides founders with essential resources to rapidly prototype and iterate their products, encompassing physical models, technology developments, user interaction studies, and comprehensive business plans. The program supports accepted teams through a combination of full-time staff, mentors, and a vibrant startup community, emphasizing the development of scalable business strategies. Once products are ready for market introduction, teams transition to San Francisco, where HAX assists with business development, fundraising, and establishing critical partnerships. The program includes specialized initiatives such as HAX Growth, a 7-week bootcamp for launching B2C and B2B hardware startups, and HAX Boost, which helps teams refine their sales and marketing strategies while preparing for growth. HAX is part of SOSV, a global venture capital firm with a diverse portfolio, focusing on technology startups that aim to create meaningful innovations.

Venture Kick, a private philanthropic initiative, provides as much 150,000 Swiss francs in pre-seed funding to Swiss startups and offers structured, entrepreneurial training to build robust, winning businesses. Entrepreneurs pitch for finance as many as three times, as they compete for increasing amounts of funding at each stage. Founders gain direct feedback from the expert juries and access to an international network of successful entrepreneurs and investors. Venture Kick has supported 600 Swiss startup projects with 24.9 million francs to date. Supported projects have incorporated as 454 active companies, creating 6,033 jobs, and attracting 2.49 billion francs worth of subsequent investment. Companies founded by Venture Kick alums represented 55 percent of the TOP 100 Swiss Startup Award 2018. In 2019 Venture Kick will support idea-stage startup projects with 4.35 million francs, to bring Swiss science to global markets.

OrbiMed is a healthcare-focused investment firm based in New York City, established in 1989. The firm specializes in providing a range of financing solutions, including bridge loans, senior debt, and structured debt capital for both commercial-stage public and private healthcare companies. OrbiMed invests across various sectors within the healthcare industry, such as pharmaceuticals, life sciences, digital health, medical devices, biopharmaceuticals, diagnostics, healthcare technology, and biotechnology. With approximately $5 billion in assets under management, OrbiMed aims to support a spectrum of healthcare companies, from early-stage ventures to established multinational corporations.

Innovate U.K. is a NPO that offers funding services to support science and technology innovations. The organization offers services and information on births, deaths, marriages, business, self-employed, childcare, parenting, citizenship, law, disabled persons, transportation, education, environment, housing, money, tax, travel, immigration, and jobs. Innovate U.K. is based in Swindon.

Khosla Ventures, founded in 2004 and headquartered in Menlo Park, California, is a venture capital firm that provides strategic advice, capital, and support to bold entrepreneurs across various sectors. The firm focuses on early-stage investments in areas such as artificial intelligence, climate technology, sustainability, enterprise solutions, consumer products, fintech, digital health, medical technology, and therapeutics. Khosla Ventures is particularly interested in innovative solutions that address significant socio-economic challenges and enhance productivity, especially for low-income populations and small businesses in emerging markets. The firm embraces experimentation and is open to investing in unconventional and high-risk ventures, often acting as the sole investor in groundbreaking projects. With a commitment to fostering impactful entrepreneurship, Khosla Ventures seeks to create value through technological advancements and creative business models, with a special emphasis on markets in South Asia.

TEDCO is an independent organization established in 1998 and located in Columbia, Maryland. It serves as the leading source of entrepreneurial business assistance and seed funding for the development of startup companies within Maryland's innovation economy. TEDCO focuses on early-stage companies across various sectors, including software, technology, energy equipment, life sciences, and oncology. Its mission is to foster innovation and economic growth in Maryland by supporting the growth of startups and enhancing the state's position in the entrepreneurial landscape.

New Enterprise Associates, Inc. is a private equity and venture capital firm founded in 1977 and headquartered in Menlo Park, California, with additional offices in India and China. The firm specializes in investing across various stages of business development, from seed funding to public offerings, with a strong emphasis on the technology and healthcare sectors. Its investment strategy encompasses a wide range of industries, including information technology, consumer internet, financial technology, software, healthcare services, life sciences, biopharmaceuticals, and energy technology. New Enterprise Associates actively engages with entrepreneurs to support the growth of their companies, making investments between $0.05 million and $20 million. The firm has a global investment focus, particularly in regions such as Asia, Brazil, and the United States.

US Department of Energy is a government agency that regulates energy policy, research, and development. The Energy Department's mission is to ensure America’s security and prosperity by addressing its energy, environmental, and nuclear challenges through transformative science and technology solutions.

Johnson & Johnson Innovation - JJDC, established in 1973 and based in New Brunswick, New Jersey, serves as the corporate venture capital arm of Johnson & Johnson. The organization focuses on accelerating early-stage innovation by fostering strategic collaborations. JJDC connects potential partners with essential resources to support advancements in transformation science and technology across various sectors, including pharmaceuticals, medical devices, consumer healthcare, and medtech. Through its investment activities, JJDC aims to drive innovation and enhance the development of new solutions that can improve health and well-being.

The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.

Enterprise Ireland is a government agency based in Dublin, Ireland, established in 1998 to foster the growth and development of indigenous businesses. Its primary mission is to assist Irish enterprises in achieving a strong presence in global markets, thereby enhancing national and regional prosperity. The agency supports a wide range of companies, from high-potential start-ups to established businesses, by providing funding, resources, and guidance. Additionally, Enterprise Ireland collaborates with college-based researchers to facilitate the development and commercialization of innovative technologies through licensing and spin-out companies. By focusing on innovation and export sales, Enterprise Ireland plays a crucial role in driving economic growth and competitiveness within the Irish economy.

Perceptive Advisors LLC is an investment management firm established in 1999, with headquarters in New York City and an additional office in Boston. The firm specializes in supporting the life sciences sector, investing primarily in biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services. Perceptive Advisors engages in venture capital and incubation, making equity investments ranging from $10 million to $200 million in both private and public companies. It manages client-focused equity portfolios and employs a long/short equity strategy as part of its hedging techniques. Additionally, the firm conducts in-house research and utilizes technical analysis to inform its investment decisions. Perceptive Advisors also provides customized debt financing solutions through its Perceptive Credit Opportunities Fund, catering to the evolving needs of healthcare companies.

Legend Capital, established in 2001 and based in Beijing, China, is a prominent venture capital firm and a subsidiary of Legend Holdings Ltd. The firm focuses on investing in high-growth ventures primarily within China or related markets, managing approximately US$700 million across multiple funds. Legend Capital emphasizes early-stage investments in the information technology sector, particularly in network applications and services, as well as in infrastructure and professional services. Additionally, it targets mid-market growth companies in consumer goods, clean technology, healthcare, equipment manufacturing, and modern services. With a portfolio of over 60 companies, Legend Capital actively supports its investments by providing extensive business resources and tailored services, aimed at enhancing business development and brand building in the Chinese market.

Panakès Partners is a venture capital firm based in Milan, Italy, founded in 2015 by Fabrizio Landi, Alessio Beverina, and Diana Saraceni. The firm focuses on investing in early-stage startups and small to medium-sized enterprises within the life sciences sector across Europe and Israel. Panakès Partners seeks out ambitious companies and teams that are developing innovative technologies and products aimed at improving global health and quality of life. With a commitment to fostering revolutionary advancements in life sciences, the firm aims to support transformative solutions that address pressing health challenges.

Medtronic is a global leader in healthcare technology, specializing in solutions for complex and chronic conditions. The company develops a wide range of medical technologies that address 70 different medical conditions, including treatments for the lungs, brain, heart, diabetes, and women's health. Its product offerings encompass patient monitoring systems, robotic surgery, insulin pumps, and cardiac devices, among others. Medtronic is committed to improving patient outcomes through innovative therapies and technologies that provide lifelong solutions, particularly for those suffering from chronic pain. With a focus on addressing diverse healthcare challenges, Medtronic leverages its extensive knowledge and dedication to enhance the lives of patients worldwide.

Alumni Ventures Group, LLC is a venture capital firm based in Manchester, New Hampshire, founded in 2013. The firm specializes in seed and early-stage investments, as well as late-stage pre-IPO opportunities, with a flexible approach that is sector and geographic agnostic. Alumni Ventures aims to provide high-quality, diversified venture portfolios to individual investors, particularly accredited alumni from top entrepreneurial schools, who may not have had access to venture capital previously. The firm focuses on backing companies that have an alumni connection and are led by established institutional investors with expertise in their respective fields. Additionally, Alumni Ventures offers focused funds that enable accredited investors to access a diverse portfolio of investments across various types, sectors, stages, and geographies.

Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in promising life science companies that exhibit strong management teams and innovative technologies or business models. While its primary investment strategy targets opportunities in China, Lilly Asia Ventures is also open to exploring prospects in other regions of East and South Asia. The firm invests across various stages, including seed, early, and later stages, with particular interest in sectors such as healthcare, life sciences, oncology, manufacturing, and technology-based industries. Through its investments, Lilly Asia Ventures aims to foster the development of innovative solutions that contribute to improved health and quality of life.

IndieBio, founded in 2014 and based in San Francisco, is the world’s first accelerator dedicated to startups that leverage biology to address significant global challenges. As part of SOSV, a global venture capital firm, IndieBio focuses on nurturing seed-stage and early-stage companies across various sectors, including healthcare, life sciences, biotechnology, and consumer products. The accelerator provides funding and support to innovative ventures aiming to create impactful solutions in areas such as pharmaceuticals, oncology, and advanced manufacturing. By fostering emerging technologies and biological applications, IndieBio plays a crucial role in advancing the next generation of startups that seek to make a positive difference in society.

Sofinnova Partners is a venture capital firm founded in 1972 and headquartered in Paris, France. The firm specializes in investing in the life sciences sector, focusing on biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. With over €2 billion in assets dedicated to life science investments, Sofinnova Partners partners with entrepreneurs at various stages, from seed to later-stage companies, including start-ups and corporate spin-offs. The firm actively seeks to take a lead role in financing, often becoming the first institutional investor in Series A rounds. It maintains an engaged presence in its portfolio companies by sitting on their boards and supporting them through to exit, thereby fostering transformative innovations that have the potential to make a significant positive impact on society.

CDP Venture Capital Sgr - National Innovation Fund aims to make venture capital a cornerstone of the country's economic development and innovation, creating the conditions for an overall and sustainable growth of the venture capital ecosystem.

Novo Holdings is a Danish holding and investment firm based in Copenhagen, wholly owned by the Novo Nordisk Foundation. Established in 1999, it manages the Foundation's financial assets and aims to ensure sufficient dividends to support its grant obligations for medical and scientific research. Novo Holdings primarily invests in the life science sector, maintaining a diverse portfolio that includes equities, bonds, real estate, infrastructure, and private investments. It holds a significant ownership stake in Novo Nordisk A/S and Novozymes A/S, ensuring a material influence over these companies. The firm actively participates in their governance and is committed to supporting early-stage applied research in life sciences through initiatives like Novo Seeds. By investing in both early and later-stage life science companies, Novo Holdings seeks to balance financial risk while aiming for high returns, all within a framework of shared values and management principles across the Novo Group.

EQT Partners AB is a private equity and venture capital firm based in Stockholm, Sweden, with a global presence through additional offices in major cities across Europe, Asia, and North America. Founded in 1994, EQT specializes in a wide array of investment strategies, including expansion capital, buyouts, and growth equity, focusing on medium to large-sized companies with consistent cash flows or significant intrinsic value. The firm targets various sectors, such as healthcare, technology, energy, and infrastructure, and emphasizes investments in mid-market situations, over-leveraged companies, and distressed assets. EQT's investment approach is characterized by taking controlling or co-controlling equity stakes in its portfolio companies and actively participating in their management, often securing board seats. The firm typically holds investments for four to eight years, aiming to enhance growth and create long-term value for stakeholders.

The Bill & Melinda Gates Foundation is an independent non-profit organization based in Seattle, Washington, established in 2000. It is dedicated to reducing global inequities by focusing on improving health, alleviating extreme poverty, and supporting educational initiatives. The foundation also engages in community giving within the Pacific Northwest, promoting strategies and programs that assist low-income families. With regional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom, the foundation is governed by its co-founders, Bill and Melinda Gates, along with trustee Warren Buffett. Its mission encompasses a wide range of global challenges, aiming to create lasting change through targeted grant-making and programmatic efforts.

Scottish Enterprise is Scotland's primary economic development agency, functioning as a non-departmental public body of the Scottish Government. Established in 1991 and based in Glasgow, it aims to enhance Scotland's economic landscape by fostering an innovative and productive economy with a strong international presence. The agency collaborates with both public and private sectors to identify and leverage opportunities for sustainable economic growth. It supports small and medium-sized enterprises (SMEs) by connecting them with appropriate funding sources, facilitating access to finance, and assisting in management and growth strategies. Scottish Enterprise specifically targets sectors such as food and drink, creative industries, financial services, renewable energy, healthcare, and biotechnology. Additionally, it partners with various investors, including business angels and venture capitalists, to strengthen the funding landscape for Scottish businesses, ultimately contributing to the broader objectives outlined in its business plan.

The European Investment Bank (EIB), established in 1958 and headquartered in Luxembourg, serves as the lending arm of the European Union, primarily focusing on supporting European integration and social cohesion. It offers a range of financial services, including project loans for both public and private sectors, loans to banks and intermediaries, and structured finance products. EIB also provides guarantees, securitization instruments, and equity investments, particularly in infrastructure and environmental projects. The bank plays a crucial role in financing microfinance and risk-sharing initiatives for research and innovation, alongside offering technical expertise for sustainable energy projects. Its advisory services encompass urban development and infrastructure, and it actively supports public-private partnerships and small to medium-sized enterprises across various sectors, including transportation, energy, health, education, and agriculture.

Gilde Healthcare Partners B.V. is a private equity and venture capital firm based in Utrecht, Netherlands, with additional offices in Cambridge, Massachusetts, and Frankfurt am Main, Germany. Established in 2000, the firm specializes in investing in the healthcare sector, focusing on healthcare technology, medtech, diagnostics, digital health, therapeutics, and healthcare services. Gilde Healthcare targets lower mid-market companies and seeks to lead investments, typically investing between €1 million and €35 million in firms with enterprise values up to €150 million. The firm emphasizes sectors such as biopharma, medical devices, clinical decision support, and various healthcare services, including primary and specialized care. Gilde Healthcare aims to take both majority and minority stakes in its portfolio companies and actively participates in their management by securing board positions. The firm primarily invests in the United States and Europe, particularly in the Benelux region.

For more than 20 years, Innovation Works has played a vital role in Southwestern PA's technology economy, investing capital, business expertise, and other resources into high-potential companies with the greatest likelihood for regional economic impact. IW is the single largest investor in seed-stage companies in the region. They also provide resources for manufacturers to adopt new technologies.

Versant Ventures is a healthcare investment firm founded in 1999 and based in San Francisco, California. It focuses on supporting exceptional entrepreneurs in building innovative companies across various sectors within healthcare, including biotechnology, life sciences, pharmaceuticals, and oncology. With $2.3 billion under management, the firm invests at all stages of company development, emphasizing the discovery and development of novel therapeutics. Versant’s team possesses extensive investment, operational, and scientific expertise, allowing for a hands-on approach to company building. Since its inception, more than 65 companies associated with Versant have successfully achieved acquisitions or initial public offerings, reflecting the firm’s commitment to fostering growth in the healthcare industry.

Ben Franklin Technology Partners of Southeastern Pennsylvania, established in 1982 and based in Philadelphia, is a prominent capital provider dedicated to the technology sectors within Pennsylvania. The organization specializes in both early-stage and established companies, with a focus on enhancing the region's innovation ecosystem across information technology, health, and physical sciences. Over its 30-year history, Ben Franklin has invested in more than 2,000 technology companies and has contributed over $170 million to drive regional growth. In addition to its investment activities, Ben Franklin fosters university and industry partnerships to facilitate the commercialization of scientific discoveries, while also supporting initiatives that bolster the local entrepreneurial community.

HSG, formerly known as Sequoia Capital China, is a prominent venture capital and private equity firm with a global focus on technology, healthcare, and consumer sectors. Established in 2005, HSG operates offices in key international cities including Hong Kong, Shanghai, Beijing, Shenzhen, London, Tokyo, and Singapore, managing over $55 billion in assets for leading institutional investors. The firm has supported over 1,500 companies, fostering innovation and entrepreneurship through investments in transformative technologies and high-growth business models. HSG has a track record of success, with more than 160 portfolio companies having gone public and over 140 achieving unicorn status. It has developed a comprehensive investment platform that encompasses seed, venture, growth, buyout, and infrastructure investing, as well as public equities. HSG is dedicated to empowering entrepreneurs and companies to create enduring enterprises while delivering strong returns to its limited partners. Through its extensive resources and industry expertise, HSG provides significant advantages to the companies it partners with.

Lumira Ventures is a venture capital firm that specializes in investing in emerging, mid, and late-stage companies within the healthcare and life sciences sectors. Founded in 2007 and headquartered in Toronto, Ontario, it has additional offices in Montreal, Vancouver, and Boston. The firm focuses on biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health companies, primarily in North America, particularly Canada and the United States. Lumira Ventures typically invests between 5 million and 15 million in its portfolio companies, which currently includes over 30 active investees. The firm collaborates closely with management teams to enhance the value of their technology pipelines through strategic financing, board participation, and facilitating access to funding sources, partners, and market opportunities. With a history of over 100 investments since 1989, Lumira Ventures is recognized for its commitment to fostering innovation and addressing significant unmet needs in healthcare.

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greater development space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services. Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns. Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise. By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.

T. Rowe Price Group is an investment management and financing advisory firm based in Baltimore, Maryland, founded in 1937. The company offers a comprehensive range of investment strategies, including debt, equities, and private equity, catering to a diverse clientele that includes individuals, high-net-worth individuals, financial institutions, retirement plan sponsors, charitable organizations, corporations, and government entities. T. Rowe Price provides services such as separate account management, mutual funds, and sub-advisory services, positioning itself as a trusted partner in managing and growing investments across various sectors. The firm is also involved in funding technology startups, reflecting its commitment to innovation and adapting to emerging market trends.

Kohlberg Kravis Roberts is a prominent global investment firm that specializes in managing a diverse range of alternative asset classes, including private equity, energy, infrastructure, real estate, and credit, as well as hedge funds through strategic partnerships. Founded in 1976, the firm focuses on generating attractive investment returns by employing a disciplined and patient investment approach. KKR is committed to driving growth and value creation in its portfolio companies while aligning its interests with those of its investment partners. The firm also provides comprehensive human resources services to enhance operational effectiveness. With a presence in multiple countries, including India and Japan, KKR continues to leverage its extensive expertise and industry knowledge to deliver value across its investment strategies.

U.S. Venture Partners (USVP), founded in 1981 and based in Menlo Park, California, is a venture capital firm that specializes in early-stage investments. The firm focuses on transformative ideas within the information technology and healthcare sectors, emphasizing innovation that drives economic growth and job creation. USVP's investment areas include enterprise software, IT security, consumer internet, mobile applications, e-commerce, healthcare, and IT-enabled healthcare services. The team at USVP comprises former entrepreneurs, technologists, corporate executives, financial professionals, and industry experts, all dedicated to supporting entrepreneurs in their journey to build impactful companies. The firm primarily targets businesses located on the West Coast of the United States, seeking opportunities in B2B, life sciences, oncology, cybersecurity, digital health, and cloud technology.

Trinity Capital Inc. is a business development company based in Chandler, Arizona, focused on providing venture debt and equipment financing to emerging growth-stage companies. Established in 2019, the company specifically targets investments in private companies, including those backed by venture capital and institutional equity investors. Trinity Capital offers a range of debt solutions, including loans, revolving credit lines, senior debt, subordinated debt, and equipment financing. The firm collaborates closely with venture capital firms and technology banks to deliver tailored financial solutions that meet the unique needs of its clients. By specializing in sectors such as healthcare, information technology, consumer products, and energy, Trinity Capital positions itself as a key partner for innovative start-ups seeking capital while aiming to preserve equity.

ShangBay Capital is a venture capital firm established in 2015 and located in Palo Alto, California. The firm specializes in investing in the life sciences sector, with a particular focus on medical devices, biotechnology, and mobile healthcare companies within the United States. As a Registered Investment Adviser, ShangBay Capital seeks to support innovative early-stage companies that are poised to make significant advancements in healthcare technology.

Kurma Partners is a Paris-based management company founded in 2009 that focuses on financing innovation in healthcare and biotechnology. It specializes in supporting therapeutic and medical advancements from pre-creation stages to development capital. The firm is recognized as a significant player in the European market, actively investing in sectors such as life sciences, health technology, pharmaceuticals, and digital health. Kurma Partners collaborates with various prestigious research institutions and hospitals to foster innovation and growth in these fields.

RA Capital Management is a Boston-based investment advisor founded in 2004, specializing in the life sciences and healthcare sectors. The firm focuses on early-stage companies developing innovative technologies, products, and services in drug development, medical devices, diagnostics, and research tools. With a team of professionals trained in biology, chemistry, and medicine, RA Capital Management leverages its extensive industry and business development experience to identify and invest in promising healthcare ventures. As a Registered Investment Adviser, the firm employs a strategic approach that includes both venture capital investments and a hedge fund strategy, targeting opportunities primarily in the United States and Europe.

Sand Hill Angels is a collective of over 60 experienced Silicon Valley technology professionals that has been active since 2000. This group focuses on investing in early-stage and growth-stage technology startups across various sectors, including clean technology, Internet startups, information sciences, and life sciences. Their expertise encompasses areas such as semiconductors, enterprise software, storage, communications, medical devices, diagnostics, and bioinformatics. Sand Hill Angels typically invests between $300,000 and $500,000 in companies with pre-money valuations under $5 million, participating in seed or Series A rounds as well as later-stage bridge investments. The group's collaborative approach extends to working with venture capital funds and other angel organizations, contributing significantly to the Bay Area's technology startup ecosystem.

UI Investissement, formerly known as UI Gestion SAS, is a private equity and venture capital firm established in 2004 and headquartered in Paris, France. The firm specializes in investments in small to mid-cap companies across various sectors, with a particular focus on healthcare, agri-food, and services industries. Over the years, UI Investissement has actively supported the growth of more than 120 small and medium-sized enterprises, investing over €550 million in their development projects. The firm aims to finance a wide range of business stages, including seed, startup, and growth capital, as well as buyouts and turnaround transactions. Its investment strategy is regionally focused, primarily targeting areas in France such as Aquitaine, Brittany, and Ile-de-France, and it typically invests between €1 million and €50 million depending on the enterprise value of the companies. UI Investissement aims to act as both a majority and minority shareholder, leveraging its experience and corporate culture to foster sustainable performance in its portfolio companies.